Candriam Luxembourg S.C.A. cut its stake in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) by 11.7% during the second quarter, Holdings Channel reports. The firm owned 53,000 shares of the company’s stock after selling 7,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Pacira Pharmaceuticals were worth $2,528,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in PCRX. BlackRock Inc. increased its position in Pacira Pharmaceuticals by 28,922.7% in the first quarter. BlackRock Inc. now owns 3,183,787 shares of the company’s stock valued at $145,180,000 after buying an additional 3,172,817 shares during the last quarter. Tudor Investment Corp ET AL bought a new position in Pacira Pharmaceuticals during the first quarter valued at about $22,867,000. Norges Bank bought a new position in Pacira Pharmaceuticals during the fourth quarter valued at about $13,258,000. Russell Investments Group Ltd. increased its position in Pacira Pharmaceuticals by 3,599.8% in the second quarter. Russell Investments Group Ltd. now owns 283,513 shares of the company’s stock valued at $13,524,000 after buying an additional 275,850 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its position in Pacira Pharmaceuticals by 788.0% in the first quarter. Ameriprise Financial Inc. now owns 282,531 shares of the company’s stock valued at $12,884,000 after buying an additional 250,714 shares during the last quarter.
Pacira Pharmaceuticals, Inc. (PCRX) opened at 36.65 on Thursday. The firm’s market capitalization is $1.47 billion. The stock’s 50 day moving average is $45.26 and its 200-day moving average is $45.37. Pacira Pharmaceuticals, Inc. has a 12 month low of $29.95 and a 12 month high of $58.95.
Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its earnings results on Wednesday, August 2nd. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.06. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The business had revenue of $70.90 million for the quarter, compared to analyst estimates of $73.37 million. During the same quarter in the prior year, the business earned $0.21 earnings per share. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. Equities analysts anticipate that Pacira Pharmaceuticals, Inc. will post ($0.13) earnings per share for the current fiscal year.
PCRX has been the topic of several research reports. Mizuho restated a “buy” rating and set a $54.00 price objective on shares of Pacira Pharmaceuticals in a report on Wednesday, July 26th. Royal Bank Of Canada set a $58.00 price objective on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, May 15th. ValuEngine downgraded shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 4th. BidaskClub downgraded shares of Pacira Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. Finally, Wedbush restated an “outperform” rating and set a $87.00 price objective on shares of Pacira Pharmaceuticals in a report on Wednesday, June 21st. Four research analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $54.50.
In other news, SVP Scott Braunstein sold 768 shares of the business’s stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $43.32, for a total value of $33,269.76. Following the transaction, the senior vice president now owns 9,982 shares in the company, valued at approximately $432,420.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Kristen Marie Williams sold 1,877 shares of the business’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $43.32, for a total transaction of $81,311.64. Following the completion of the transaction, the chief accounting officer now owns 13,773 shares in the company, valued at approximately $596,646.36. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,564 shares of company stock worth $2,506,682. 6.60% of the stock is owned by corporate insiders.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX).
Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.